swisspartners Ltd. Acquires 5,858 Shares of Johnson & Johnson (NYSE:JNJ)

swisspartners Ltd. raised its holdings in Johnson & Johnson (NYSE:JNJGet Rating) by 138.5% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 10,088 shares of the company’s stock after buying an additional 5,858 shares during the quarter. Johnson & Johnson accounts for 3.4% of swisspartners Ltd.’s investment portfolio, making the stock its 9th largest holding. swisspartners Ltd.’s holdings in Johnson & Johnson were worth $4,825,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Magnolia Capital Management Ltd. grew its position in shares of Johnson & Johnson by 0.5% during the 1st quarter. Magnolia Capital Management Ltd. now owns 11,162 shares of the company’s stock valued at $1,978,000 after acquiring an additional 55 shares during the period. Howard Financial Services LTD. boosted its holdings in Johnson & Johnson by 2.1% in the 1st quarter. Howard Financial Services LTD. now owns 2,757 shares of the company’s stock worth $489,000 after buying an additional 57 shares during the last quarter. American Financial Advisors LLC boosted its holdings in Johnson & Johnson by 2.1% in the 1st quarter. American Financial Advisors LLC now owns 2,715 shares of the company’s stock worth $481,000 after buying an additional 57 shares during the last quarter. Capital Investment Counsel Inc boosted its holdings in Johnson & Johnson by 0.8% in the 4th quarter. Capital Investment Counsel Inc now owns 7,796 shares of the company’s stock worth $1,334,000 after buying an additional 59 shares during the last quarter. Finally, Kwmg LLC boosted its holdings in Johnson & Johnson by 2.6% in the 1st quarter. Kwmg LLC now owns 2,354 shares of the company’s stock worth $417,000 after buying an additional 59 shares during the last quarter. 68.78% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, EVP Kathryn E. Wengel sold 40,000 shares of the business’s stock in a transaction on Friday, June 10th. The shares were sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the completion of the transaction, the executive vice president now owns 71,311 shares in the company, valued at $12,336,803. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, EVP Kathryn E. Wengel sold 40,000 shares of the business’s stock in a transaction on Friday, June 10th. The shares were sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the completion of the transaction, the executive vice president now owns 71,311 shares in the company, valued at $12,336,803. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CAO Robert J. Decker sold 8,462 shares of the business’s stock in a transaction on Thursday, May 26th. The stock was sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the transaction, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at approximately $2,785,140. The disclosure for this sale can be found here. Insiders own 0.35% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on JNJ. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, May 17th. SVB Leerink decreased their target price on shares of Johnson & Johnson from $200.00 to $194.00 in a research note on Wednesday, July 20th. Daiwa Capital Markets initiated coverage on shares of Johnson & Johnson in a research note on Wednesday, June 22nd. They issued an “outperform” rating on the stock. Raymond James raised their target price on shares of Johnson & Johnson from $195.00 to $196.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 20th. Finally, Citigroup decreased their target price on shares of Johnson & Johnson from $205.00 to $201.00 in a research note on Wednesday, July 20th. Four equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus price target of $189.89.

Johnson & Johnson Stock Down 1.6 %

Johnson & Johnson stock opened at $171.79 on Friday. Johnson & Johnson has a fifty-two week low of $155.72 and a fifty-two week high of $186.69. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.14 and a current ratio of 1.42. The firm has a 50 day moving average price of $175.41 and a 200 day moving average price of $174.52. The company has a market capitalization of $451.67 billion, a PE ratio of 25.01, a price-to-earnings-growth ratio of 3.29 and a beta of 0.59.

Johnson & Johnson (NYSE:JNJGet Rating) last posted its quarterly earnings results on Tuesday, July 19th. The company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.57 by $0.02. The business had revenue of $24.02 billion during the quarter, compared to the consensus estimate of $23.85 billion. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.14%. The company’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.48 earnings per share. Research analysts expect that Johnson & Johnson will post 10.05 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 6th. Shareholders of record on Tuesday, August 23rd will be paid a $1.13 dividend. The ex-dividend date of this dividend is Monday, August 22nd. This represents a $4.52 annualized dividend and a dividend yield of 2.63%. Johnson & Johnson’s dividend payout ratio (DPR) is 65.79%.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Want More Great Investing Ideas?

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.